CT引导下子宫内膜癌3D腔内近距离治疗计划的剂量学分析

doi:10.3760/cma.j.issn.1004-4221.2015.05.024

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (382 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的通过比较子宫内膜癌腔内近距离治疗3D计划和2D计划,探讨子宫内膜癌3D腔内近距离治疗的剂量学特性。方法回顾性分析11例子宫内膜癌患者的39次3D近距离治疗计划并重新设计2D计划,从DVH上比较靶区V₁₅₀、D₉₀,膀胱、直肠、小肠及乙状结肠D_{2 cm³} 。采用配对t检验方法分析组间差异。结果靶体积<60 cm³时,3D、2D计划靶区D₉₀分别为(551.17±90.33)、(574.15±117.18) cGy (P=0.390),随着靶体积增加3D计划的D₉₀增加(P=0.001)。3D、2D计划靶区V₁₅₀分别为(51.05±21.61)、(53.41±11.71) cm³(P=0.482)。当靶体积>60 cm³时,与2D计划相比,3D计划提高靶区覆盖同时增加了危及器官受量,但小肠受量增加不明显(P=0.128)。此外,不同计划模式下BMI增加对直肠、小肠、膀胱及乙状结肠的受量无显著影响,P值分别为0.239、0.198、0.744和0.834。结论子宫内膜癌3D腔内近距离治疗与2D计划相比可显著提高较大靶区的覆盖范围,有效控制OAR受量,临床疗效与不良反应尚需进一步观察。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	于浪
	张宇
	孙显松
	王欣海
	晏俊芳
	杨波
	邱杰

关键词 ：子宫内膜癌/三维腔内近距离疗法, 剂量体积直方图, 体重指数

Abstract：Objective To study the dosimetric peculiarity of 3D intracavitary brachytherapy in the application of endometrial carcinoma comparing with traditional 2D plans. Method 39 3D brachytherapy treatment plans of 11 patients with endometrial carcinoma were retrospectively analyzed with re-planning 2D treatment plan, the dose volume histogram (DVH) parameters such as the target dose volume parameters V₁₅₀ and D₉₀, the 2-cc doses to organs such as bladder,small intestine,rectum and sigmoid and the total reference air kerma TRAK were analyzed. The differences between the two groups are compared by paired samples T test. Results For target with V<60 cm³,there is no statistically significant difference between 2D and 3D plans,the D₉₀ is (551.17±90.33) cGy and (574.15±117.18) cGy,respectively (P=0.390). As the increase of target volume,the D₉₀ came to be significantly different (P=0.001), high dose region V₁₅₀ for 3D and 2D plans is (51.05±21.61) cm³ and (53.41±11.71) cm³, respectively (P=0.482). With the target volume larger than 60 cm³,compare to 2D plans, the 3D plan can increase the target coverage as well as OAR dose except for small intestine (P=0.128). In addition, with different plan mode,the BMI did not affect the crisis organ dose such as rectum,small intestine, bladder and sigmoid,the P value is 0.239,0.198,0.744 and 0.834,respectively. Conclusions For endometrial carcinoma,compared with traditional two-dimensional plans,the 3D brachytherapy treatment plans can significantly improve the target coverage and avoiding overdose of organs, clinical curative effect and side effect still needs further observation.

Key words： Endometrial carcinoma/three-dimensional intracavitary brachytherapy Dose volume histogram Body mass index

通讯作者: 邱杰,E-mail:qj_ww@139.com

引用本文:

于浪,张宇,孙显松等. CT引导下子宫内膜癌3D腔内近距离治疗计划的剂量学分析[J]. 中华放射肿瘤学杂志, 2015, 24(5): 569-572.

Yu Lang,Zhang Yu,Sun Xiansong et al. Dosimetric analysis of computed tomography guided three-dimensional intracavitray brachytherapy in endometrial carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 569-572.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2015.05.024 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2015/V24/I5/569

[1] McMeekin SD, Alektiar KM, Sabbatini P.section Ⅲ:disease sites[A]//Barakat RR, Makman M, Randall M. Principles and practice of gynecologic oncology[M]. 5^th ed. Philadelphia:Lippincott Williams & Wilkins,2009:683-732.
[2] 孔为民,孙建衡.59例子宫内膜癌单纯放射治疗[J].中华放射肿瘤学杂志,2000,9(3):184-186.
[3] Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from gynecological (GYN) GEC-ESTRO working group (I):concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol,2005,74(3):235-245.
[4] Selke P, Roman TN, Souhami L, et al. Treatment results of high dose rate brachytherapy in patients with carcinoma of the cervix[J]. Int J Radiat Oncol Biol Phys,1993,27(4):803-809.
[5] Wegner RE, Beriwal S, Heron DE, et al. Definitive radiation therapy for endometrial cancer in medically inoperable elderly patients[J]. Brachytherapy,2010,9(3):260-265.
[6] Caon J, Holloway C, Dubash R, et al. Evaluating adjacent organ radiation doses from postoperative intracavitary vaginal vault brachytherapy for endometrial cancer[J]. Brachytherapy,2014,13(1):94-99. DOI:10.1016/j.brachy.2013.09.007.
[7] Podzielinski I, Randall ME, Breheny PJ, et al. Primary radiation therapy for medically inoperable patients with clinical stage Ⅰ and Ⅱ endometrial carcinoma[J]. Gynecol Oncol,2012,124(1):36-41.DOI:10.1016/j.ygyno.2011.09.022.
[8] 安奇,杨靖,朱越.磁共振弥散加权成像及增强扫描在早期子宫内膜癌分期中的应用[J].中国医学科学院学报,2012,34(5):486-491.DOI:10.388l/j.issn.1000.503X.2012.05.009.
[9] Beriwal S, Kim H, Heron DE, et al. Comparison of 2D vs. 3D dosimetry for Rotte ‘Y’ applicator high dose rate brachytherapy for medically inoperable endometrial cancer[J]. Technol Cancer Res Treat,2006,5(2):521-527.
[10] Nag S, Erickson B, Parikh S, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium[J].Int J Radiat Oncol Biol Phys,2000,48(3):779-790.
[11] Boyle JM, Craciunescu O, Steffey B, et al. Body mass index, dose to organs at risk during vaginal brachytherapy, and the role of three-dimensional CT-based treatment planning[J]. Brachytherapy,2014,13(4):332-336. DOI:10.1016/j.brachy.2013.12.002.